SanBio Inc. presented a business plan aiming to become a global leader in brain regeneration by pioneering the world\u2019s first brain regenerative medicine, Akougo\u00ae.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4592","jir_company_name":"SanBio Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4592-20260423-01.pdf","jir_short_summary":"SanBio Inc. presented a business plan aiming to become a global leader in brain regeneration by pioneering the world\u2019s first brain regenerative medicine, Akougo\u00ae.","jir_summary":"### Business Overview and Vision\nSanBio Inc. has developed Akougo\u00ae, the world\u2019s first brain regenerative medicine targeting chronic phase motor paralysis resulting from traumatic brain injury, which received conditional and time-limited approval in Japan in July 2024. The company\u2019s mission is to become a global leader in brain regeneration by delivering value to patients and stakeholders through the development of regenerative medicine products.\n\n### Business Model and Pipeline\nThe company engages in research, development, manufacturing, and sales of cell therapies, primarily targeting central nervous system disorders. Its main product is SB623 (Akougo\u00ae), with development underway for treatments for a range of conditions including chronic phase traumatic brain injury, cerebral infarction, cerebral hemorrhage, and age-related macular degeneration. Clinical trials at various phases are ongoing, aiming to obtain approvals in the U.S. and Japan.","jir_financial_highlights":"Capital: 8,375 million yen (Unknown)\nNumber of Employees: Consolidated: 33 \/ Non-consolidated: 33 (Unknown)","jir_category":"","jir_hashtags":"#SanBio, #BusinessPlan, #RegenerativeMedicine, #Biotechnology, #JapaneseStocks","jir_key_figures":"Capital: 8,375 million yen\nNumber of Employees: 33 consolidated, 33 non-consolidated (as of January 31, 2026)\nMain Product: Brain regenerative medicine SB623 (Akougo\u00ae)","jir_meta_title":"SanBio: Business Plan and Growth Strategy for Brain Regenerative Medicine Akougo\u00ae | April 2026","jir_meta_description":"Following conditional approval for the world\u2019s first brain regenerative medicine Akougo\u00ae, SanBio Inc. announced its business plan and pipeline aiming to become a global leader in brain regeneration.","jir_og_title":"SanBio: Business Plan and Growth Strategy for Brain Regenerative Medicine Akougo\u00ae","jir_og_description":"SanBio disclosed a business plan centered on Akougo\u00ae, the world\u2019s first brain regenerative medicine, aiming to innovate treatments for brain diseases.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":9416,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-41923","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n